The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma
Official Title: A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma
Study ID: NCT02749617
Brief Summary: This pilot study will investigate the impact of dexamethasone (DEX) on anti-Xa levels in participants taking apixaban 2.5 mg twice a day by mouth (PO BID). Investigators propose a prospective, cohort study of 24 participants with multiple myeloma, in whom a lenalidomide-dexamethasone (LEN-DEX)-based myeloma treatment regimen is indicated. Eligible participants will initiate thromboprophylaxis with apixaban prior to starting their DEX-containing regimen and continue until the end of cycle 3. Anti-Xa levels, D-Dimer and plasma drug concentration will be measured. This pilot study looks to investigate this potential interaction between apixaban and dexamethasone to see if it warrants further investigation in a larger study. The sample size of 24 provides 90% power to detect a primary outcome of ≥ 50% reduction in peak anti-Xa levels from baseline. Secondary outcomes include changes in plasma apixaban levels, D-dimer, and symptomatic venous thromboembolism (VTE) and bleeding during a 3-month treatment period.
Detailed Description: Study has terminated due to poor enrollment.
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Vancouver General Hospital, Vancouver, British Columbia, Canada
Name: Agnes YY Lee, MD MSc FRCPC
Affiliation: University of British Columbia, Division of Hematology
Role: PRINCIPAL_INVESTIGATOR